(2026). A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2‐Positive Metastatic Breast Cancer. Cancer Medicine.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2‐Positive Metastatic Breast Cancer."
Cancer Medicine 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2‐Positive Metastatic Breast Cancer."
Cancer Medicine, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.